Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 1996

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2009

Conditions
Anaplastic Astrocytoma
Interventions
DRUG

Antineoplaston therapy (Atengenal + Astugenal)

"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."

Trial Locations (1)

77055-6330

Burzynski Clinic, Houston

Sponsors
All Listed Sponsors
lead

Burzynski Research Institute

OTHER